<DOC>
	<DOCNO>NCT00059202</DOCNO>
	<brief_summary>This multicenter , randomize , control trial high dose ursodiol versus placebo patient primary sclerosing cholangitis ( PSC ) . The average duration follow-up approximately five year important clinical endpoint death , eligibility liver transplantation , change histology cholangiogram well liver biochemistry quality life data collect .</brief_summary>
	<brief_title>Trial High-dose Urso Primary Sclerosing Cholangitis</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Chronic cholestatic disease least six month ' duration . Serum alkaline phosphatase least 1 Â½ time upper limit normal . Retrograde , operative , percutaneous , magnetic resonance cholangiography demonstrate intrahepatic and/or extrahepatic biliary duct obstruction , beading , narrow consistent PSC within one year study entry . Liver biopsy previous one year available review compatible diagnosis PSC . Compatible biopsy feature include fibrous cholangitis , ductopenia periportal inflammation biliary fibrosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Urso</keyword>
	<keyword>PSC</keyword>
</DOC>